Skip to main content

Table 3 Hypothesized effect after 1 year of treatment on the primary endpoint

From: The ASAMET trial: a randomized, phase II, double-blind, placebo-controlled, multicenter, 2 × 2 factorial biomarker study of tertiary prevention with low-dose aspirin and metformin in stage I-III colorectal cancer patients

Treatment arm N NFκB % change 1-β (power)
Arm A (placebo) 40 + 5%
Arm B (metformin) 40 −13.5% 90%
Arm C (aspirin) 40 -13.5% 90%
Arm D (aspirin+metformin) 40 −55% (~ 3.0-fold the main effects) 80%
\